BioNTech said today it agreed to acquire the operational antibody generation unit of MAB Discovery for an undisclosed price, in a deal that builds on two collaborations by the companies stretching back nearly six years.
The acquisition also expands the top privately-held developer of RNA-based therapeutics further into monoclonal antibody (mAb) development, with new treatments that combine the technologies in mind.
Based in Neuried, Bavaria, Germany, MAB Discovery uses a proprietary rabbit-based discovery platform to generate and develop monoclonal antibodies that are designed to target traditional proteins and receptors, as well as a wide variety of more . . .